BioSpace News Archive

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021.

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial

BIOLASE, Inc., the global leader in dental lasers, announced that it has entered into an underwriting agreement with Maxim Group LLC under which the underwriters have agreed to purchase, on a firm commitment basis, 14,000,000 shares of common stock of the Company, at a price to the public of $1.03 per share less underwriting discounts and commissions.

The Galien Foundation announced today an upcoming webinar series that will explore the critical role digital technologies play in today’s life sciences, specifically in clinical trials and the development of the COVID-19 vaccines.

InMed Pharmaceuticals Inc. today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately US$4.5 million at a price of US$4.25 per unit in a private placement of its equity securities.

Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the pricing of its public offering of 3,049,130 American Depositary Shares (“ADSs”) at a public offering price of $22.75 per ADS.

EastWest Bioscience (the “Company” or “EastWest”) (TSXV:EAST) announces, subject to its stock option plan, the grant of 1,720,000 stock options to certain directors, officers, employees and consultants issued pursuant to the Company’s stock option plan.

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual General Shareholders’ Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.

Canada’s universal, publicly funded health care system is a source of pride for Canadians.

Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced phase III results. Sinovac had started its phase III trials on CoronaVac, its COVID-19 vaccine, on July 21, 2020. Trials were conducted in Brazil, Turkey, Indonesia, and Chile. In compliance with the principles of Good Clinical Practice (GCP),